Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy
Nicolò Rigamonti, Matteo Bellone
Cancer Immunology Immunotherapy (2012) Vol. 61, Iss. 4, pp. 453-468
Open Access | Times Cited: 21

Showing 21 citing articles:

Immune Infiltration and Prostate Cancer
Amy Strasner, Michael Karin
Frontiers in Oncology (2015) Vol. 5
Open Access | Times Cited: 177
Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer
Manja Idorn, Tania Køllgaard, Per Kongsted, et al.
Cancer Immunology Immunotherapy (2014) Vol. 63, Iss. 11, pp. 1177-1187
Closed Access | Times Cited: 170
Trichomonas vaginalis homolog of macrophage migration inhibitory factor induces prostate cell growth, invasiveness, and inflammatory responses
Olivia Twu, Daniele Dessì, Anh Vu, et al.
Proceedings of the National Academy of Sciences (2014) Vol. 111, Iss. 22, pp. 8179-8184
Open Access | Times Cited: 163
Ways to Enhance Lymphocyte Trafficking into Tumors and Fitness of Tumor Infiltrating Lymphocytes
Matteo Bellone, Arianna Calcinotto
Frontiers in Oncology (2013) Vol. 3
Open Access | Times Cited: 148
Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33
Iryna Saranchova, Jeffrey S. Han, Hui Huang, et al.
Scientific Reports (2016) Vol. 6, Iss. 1
Open Access | Times Cited: 69
A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer
Daniela Fenoglio, Paolo Traverso, Alessia Parodi, et al.
Cancer Immunology Immunotherapy (2013) Vol. 62, Iss. 6, pp. 1041-1052
Open Access | Times Cited: 62
Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy
Angela Rita Elia, Matteo Grioni, Veronica Basso, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 9, pp. 2171-2181
Open Access | Times Cited: 52
Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses
Elena Jachetti, Stefania Mazzoleni, Matteo Grioni, et al.
OncoImmunology (2013) Vol. 2, Iss. 5, pp. e24520-e24520
Open Access | Times Cited: 42
Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis
Sara Caputo, Matteo Grioni, Chiara Svetlana Brambillasca, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 28
Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma
Angela Rita Elia, Sara Caputo, Matteo Bellone
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 29
Prostate cancer health disparities: An immuno-biological perspective
Sanjay Kumar, Rajesh Singh, Shalie Malik, et al.
Cancer Letters (2017) Vol. 414, pp. 153-165
Open Access | Times Cited: 24
Booster Vaccinations against Cancer Are Critical in Prophylactic but Detrimental in Therapeutic Settings
Alessia Ricupito, Matteo Grioni, Arianna Calcinotto, et al.
Cancer Research (2013) Vol. 73, Iss. 12, pp. 3545-3554
Open Access | Times Cited: 23
Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes
Elizabeth M. Peek, Song Wang, Hanwei Zhang, et al.
The Prostate (2015) Vol. 75, Iss. 5, pp. 463-473
Closed Access | Times Cited: 12
Prostate cancer vaccines
Agnieszka Michael, Kate Relph, Nicola Annels, et al.
Expert Review of Vaccines (2013) Vol. 12, Iss. 3, pp. 253-262
Open Access | Times Cited: 12
Immunosuppression via Tenascin-C
Matteo Bellone, Sara Caputo, Elena Jachetti
Oncoscience (2015) Vol. 2, Iss. 8, pp. 667-668
Open Access | Times Cited: 6
Ultrasound-guided intra-tumor injection of combined immunotherapy cures mice from orthotopic prostate cancer
Giorgio Mauri, Claudia Chiodoni, Mariella Parenza, et al.
Cancer Immunology Immunotherapy (2013) Vol. 62, Iss. 12, pp. 1811-1819
Open Access | Times Cited: 4
Protein flexibility and conformational states ofLeishmaniaantigen eIF-4A: identification of a novel plausible protein adjuvant using comparative genomics and molecular modeling
Ning-Ning Wei, Adel Hamza, Ce Hao, et al.
Journal of Biomolecular Structure and Dynamics (2012) Vol. 31, Iss. 8, pp. 841-853
Closed Access | Times Cited: 4
The new aspects of immunotherapy in prostate cancer
Mostafa Ghanei, Majid Shohrati, Amin Saburi
Cancer Immunology Immunotherapy (2012) Vol. 61, Iss. 12, pp. 2375-2376
Closed Access | Times Cited: 3
Crosstalk Between Prostate Cancer Stem Cells and Immune Cells: Implications for Tumor Progression and Resistance to Immunotherapy
Matteo Bellone, Sara Caputo
Resistance to targeted anti-cancer therapeutics (2019), pp. 173-221
Closed Access | Times Cited: 3
Vitamin D-binding protein-derived macrophage-activating factor, GcMAF, and prostate cancer
Matteo Bellone, Nicolò Rigamonti
Cancer Immunology Immunotherapy (2012) Vol. 61, Iss. 12, pp. 2377-2378
Open Access | Times Cited: 2
Regulation of the Prostate Cancer Tumor Microenvironment
Arnold I. Chin
(2015)
Open Access
Page 1

Scroll to top